Exact Mass: 411.0921

Exact Mass Matches: 411.0921

Found 127 metabolites which its exact mass value is equals to given mass value 411.0921, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Mandipropamid

Pesticide4_Mandipropamid_C23H22ClNO4_2-(4-Chlorophenyl)-N-{2-[3-methoxy-4-(2-propyn-1-yloxy)phenyl]ethyl}-2-(2-propyn-1-yloxy)acetamide

C23H22ClNO4 (411.1237)

D016573 - Agrochemicals D010575 - Pesticides CONFIDENCE standard compound; EAWAG_UCHEM_ID 3061

Altanserin

3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-2-sulfanylidene-1,2,3,4-tetrahydroquinazolin-4-one

C22H22FN3O2S (411.1417)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Altanserin can synthesize Fluorine-18 Altanserin. Fluorine-18 Altanserin binds to the brain 5HT2 receptors[1].

Gonyautoxin I

{4-[(carbamoyloxy)methyl]-5,10,10-trihydroxy-2,6-diimino-decahydropyrrolo[1,2-c]purin-9-yl}oxidanesulfonic acid

C10H17N7O9S (411.0808)

Gonyautoxin I is found in mollusks. Gonyautoxin I is produced by Gonyaulax and Protogonyaulax species and isolated from shellfish. Neurotoxin, causal agent, with Saxitoxin, of shellfish poisoning. From Gonyaulax and Protogonyaulax subspecies Gonyautoxin IV is found in mollusks. D009676 - Noxae > D011042 - Poisons > D008978 - Mollusk Venoms D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D011042 - Poisons > D014688 - Venoms

Tiagabine hydrochloride

C20H26ClNO2S2 (411.1093)

D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D058805 - GABA Uptake Inhibitors C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D018377 - Neurotransmitter Agents > D018682 - GABA Agents D049990 - Membrane Transport Modulators Tiagabine hydrochloride is a potent and selective GABA reuptake inhibitor, used as an anticonvulsant agent, with IC50s of 67, 446 and 182 nM for [3H]GABA uptake in Synaptosomes, Neurons and Glia, respectively[1].

Ipratropium bromide

C20H30BrNO3 (411.1409)

R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03B - Other drugs for obstructive airway diseases, inhalants > R03BB - Anticholinergics R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3][4][5].

Carboxycelecoxib

4-(1-(4-(Aminosulfonyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)benzoic acid

C17H12F3N3O4S (411.0501)

Carboxycelecoxib is a metabolite of celecoxib (PMID: 10681375). Celecoxib (trade name: Celebrex) is a sulfa non-steroidal anti-inflammatory drug (NSAID) and selective COX-2 inhibitor used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation, and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer. Celecoxib is available by prescription in capsule form (Wikipedia).

Sulfociprofloxacin

1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-sulfO-1-piperazinyl)-3-quinolinecarboxylic acid

C17H18FN3O6S (411.09)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones

Cetocycline

3-acetyl-1-amino-4,4a,6,7-tetrahydroxy-8,11-dimethyl-1,2,4a,5,12,12a-hexahydrotetracene-2,5-dione

C22H21NO7 (411.1318)

Lintitript

2-(2-{[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl}-1H-indol-1-yl)acetic acid

C20H14ClN3O3S (411.0444)

D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists D006133 - Growth Substances > D010937 - Plant Growth Regulators > D007210 - Indoleacetic Acids C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist

Sulfo-ciprofloxacin

1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-2-sulphO-1,4-dihydroquinoline-3-carboxylic acid

C17H18FN3O6S (411.09)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones

N-(4-((5-(3-(2-Aminoethyl)-1H-indol-5-yl)-1,2,4-oxadiazol-3-yl)methyl)phenyl)methanesulfonamide

N-[4-({5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl}methyl)phenyl]methanesulphonamide

C20H21N5O3S (411.1365)

1-O-(3-Hydroxybutyryl)pancratistatin

C18H21NO10 (411.1165)

4-[3-(trifluoromethyl)phenyl]-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazole-3-thiol

C18H16F3N3O3S (411.0864)

4-[[4-(4-fluorophenyl)-3-piperidinyl]methoxy]-2-methoxy-, hydrogen sulfate (ester), (3S-trans)-Pheno

C19H22FNO6S (411.1152)

Met Met Met

C15H29N3O4S3 (411.132)

Sulfociprofloxacin

C17H18FN3O6S (411.09)

An organosulfonic acid that is ciprofloxacin carrying a sulfo group at position 4 of the piperazine ring. It is a metabolite of ciprofloxacin. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones

Ethanone

1-[4-(6-bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone

C21H18BrNO3 (411.047)

celecoxib carboxylic

C17H12F3N3O4S (411.0501)

Gonyautoxin IV

C10H17N7O9S (411.0808)

(4-(N-Benzyl-N-(4-methoxybenzyl)sulfamoyl)phenyl)boronic acid

C21H22BNO5S (411.1312)

Resorufin β-D-glucuronide sodium salt

C18H14NNaO9 (411.0566)

N-(4-acetylphenyl)-4-hydroxy-N-[(4-methoxyphenyl)methyl]benzenesulfonamide

C22H21NO5S (411.114)

4-(4-TERT-BUTYLPHENYL)-N-(2-CHLOROPHENYL)-5-CYAN-AMIDE-4,5-DIHYDRO-1,3,4-THIADIAZOLE-2-CARBOXAMIDE

C20H18ClN5OS (411.0921)

Cadrofloxacin

C19H20F3N3O4 (411.1406)

2,3,5-TRI-O-ACETYL-8-FLUORO ADENOSINE

C16H18FN5O7 (411.119)

2.4.6-TRICHLORO-1.3.5-TRIPHENYLBORAZINE

C18H15B3Cl3N3 (411.0611)

Oxitropium Bromide

C19H26BrNO4 (411.1045)

ZM 323881 HCl

ZM 323881 hydrochloride

C22H19ClFN3O2 (411.115)

O-benzyl-L-methionine toluene-p-sulphonate

C19H25NO5S2 (411.1174)

4(1H)-Pyridazinone, 6-methyl-3-(2-quinolinylmethoxy)-1-(3-(trifluorome thyl)phenyl)-

C22H16F3N3O2 (411.1195)

(9H-Fluoren-9-yl)methyl 2,4-dichloro-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate

C21H15Cl2N3O2 (411.0541)

G-1

1-(4-(6-Bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone

C21H18BrNO3 (411.047)

C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen

Thiazolidine, 2-(4-methylphenyl)-3-[(4-phenoxyphenyl)sulfonyl]- (9CI)

C22H21NO3S2 (411.0963)

2,3,5-Tri-O-acetyl-2-fluoroadenosine

C16H18FN5O7 (411.119)

L-694247

N-(4-((5-(3-(2-Aminoethyl)-1H-indol-5-yl)-1,2,4-oxadiazol-3-yl)methyl)phenyl)methanesulfonamide

C20H21N5O3S (411.1365)

4-[1-[4-(AMINOSULFONYL)PHENYL]-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-5-YL]BENZOIC ACID

C17H12F3N3O4S (411.0501)

Trimethionine

H-Met-Met-Met-OH

C15H29N3O4S3 (411.132)

9-Mesityl-10-methylacridinium perchlorate

C23H22ClNO4 (411.1237)

Sofosbuvir metabolites GS566500

C13H19FN3O9P (411.0843)

Darinaparsin

(2S,3S,4R)-3-[4-[2-(2-fluorophenyl)ethynyl]phenyl]-4-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-2-azetidinecarbonitrile

C25H18FN3O2 (411.1383)

(1S,2aS,8bS)-N-(4-chlorophenyl)-2-[cyclopropyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

C22H22ClN3O3 (411.135)

(1R,2aR,8bR)-N-(4-chlorophenyl)-2-[cyclopropyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide

C22H22ClN3O3 (411.135)

Asp-Asp-Tyr

C17H21N3O9 (411.1278)

(2-amino-5,10,10-trihydroxy-6-imino-9-sulfooxy-3a,4,8,9-tetrahydro-1H-pyrrolo[1,2-c]purin-4-yl)methyl carbamate

C10H17N7O9S (411.0808)

Lintitript

SR 27897(Lintitript)

C20H14ClN3O3S (411.0444)

Celecoxib Carboxylic Acid

4-(1-(4-(Aminosulfonyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)benzoic acid

C17H12F3N3O4S (411.0501)

Gonyautoxin I

C10H17N7O9S (411.0808)

N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonate

C15H19N6O8 (411.1264)

A hydroxy monocarboxylic acid anion that is the conjugate base of N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine, obtained by deprotonation of the carboxy group; major species at pH 7.3.

Gonyautoxin 1

C10H17N7O9S (411.0808)

LPC 7:3;O3

C15H26NO10P (411.1294)

LPS 8:3;O2

C14H22NO11P (411.093)

Met-Met-Met

C15H29N3O4S3 (411.132)

VU6019650

C18H22FN3O3S2 (411.1087)

VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR (IC50=36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide (HY-101372A) induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA)[1][2].

3,4-dihydroxyphenethyl

C19H23BrClNO2 (411.0601)

{"Ingredient_id": "HBIN007409","Ingredient_name": "3,4-dihydroxyphenethyl","Alias": "NA","Ingredient_formula": "C19H23BrClNO2","Ingredient_Smile": "C1CN(CCC1C2=CC=C(C=C2)Cl)CCC3=CC(=C(C=C3)O)O.Br","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "32830","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

(1r,4ar,12as)-3-acetyl-1-amino-4,4a,6,7-tetrahydroxy-8,11-dimethyl-12,12a-dihydro-1h-tetracene-2,5-dione

C22H21NO7 (411.1318)

[5,10,10-trihydroxy-2,6-diimino-9-(sulfooxy)-hexahydropyrrolo[1,2-c]purin-4-yl]methoxycarboximidic acid

C10H17N7O9S (411.0808)

(2s,3r,4s,5r,6s)-6-(4-{[(2-ethoxy-2-sulfanylideneethylidene)amino]methyl}phenoxy)-4,5-dihydroxy-2-methyloxan-3-yl acetate

C19H25NO7S (411.1352)

(3as,4r,9r,10as)-6-amino-10,10-dihydroxy-4-[(c-hydroxycarbonimidoyloxy)methyl]-2-imino-9-(sulfooxy)-1h,3h,3ah,4h,8h,9h-pyrrolo[1,2-c]purin-5-ium-5-olate

C10H17N7O9S (411.0808)

(5r,8s,9r)-8-benzoyl-2-(5-ethylfuran-2-yl)-6,9-dihydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one

C22H21NO7 (411.1318)

(1r,2r,3s,4s,4ar,11br)-2,3,4,6,7-pentahydroxy-1h,2h,3h,4h,4ah,9h,11bh-[1,3]dioxolo[4,5-j]phenanthridin-1-yl (3s)-3-hydroxybutanoate

C18H21NO10 (411.1165)